Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

NCT05371730 is registered in ClinicalTrials.gov with Nuwacell Biotechnologies Co., Ltd. as lead sponsor.

NCT NCT05371730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05371730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
Lead sponsor
Nuwacell Biotechnologies Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 30, 2022
Completion date
April 30, 2026
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed / refractory myelodysplastic syndromes